Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to the intravenous pharmacological interventions—specifically **ondansetron** and **dexamethasone**—evaluated in a clinical trial conducted by **Minia University** (NCT03440307). The study was designed as a randomized, double-blind trial to compare the efficacy of these two agents in preventing **post-dural puncture headache (PDPH)** and **postoperative nausea and vomiting (PONV)** in parturients undergoing elective Caesarean section under spinal anesthesia. Ondansetron is a selective 5-HT3 receptor antagonist typically used as an antiemetic, while dexamethasone is a potent synthetic glucocorticoid with anti-inflammatory and antiemetic properties. The trial aimed to determine if either drug could effectively reduce the incidence of PDPH, a common complication of spinal anesthesia, alongside their established roles in managing PONV.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on intravenous drug-Minia University-post-dural puncture headache-postoperative nausea and vomiting.